Related Experiment Video

Updated: Jul 5, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

The Critical Role of PPARgamma in Human Malignant Melanoma

Christian Freudlsperger1, Udo Schumacher, Siegmar Reinert

  • 1Department of Oral and Maxillofacial Plastic Surgery, Tübingen University Hospital, Osianderstrasse 2-8, 72076 Tübingen, Germany.

PPAR Research
|May 17, 2008
PubMed

Insights

Melanoma treatment has seen minimal progress, with metastatic survival remaining poor due to chemoresistance. This review explores Peroxisome proliferator-activated receptor gamma (PPARgamma) as a potential therapeutic target for melanoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Melanoma therapy has shown limited improvement over 30 years, with metastatic survival rates stagnating at 6-8 months.
  • Melanoma's chemoresistance stems from enhanced survival pathways and inhibited apoptosis, necessitating novel therapeutic strategies.
  • Peroxisome proliferator-activated receptors (PPARs), particularly PPARgamma, are implicated in various cancers, showing potential anticancer effects.

Purpose of the Study:

  • To review the role of PPARgamma in melanoma.
  • To evaluate the potential of PPARgamma agonists as a targeted therapy for melanoma.
  • To discuss the conflicting results and side effects associated with PPARgamma agonists in melanoma treatment.

Main Methods:

  • Literature review of studies investigating PPARgamma and its agonists in melanoma.
  • Analysis of research on the mechanisms of chemoresistance and apoptosis resistance in melanoma.
  • Synthesis of data on the efficacy and safety of PPARgamma agonists in preclinical and clinical settings.

Main Results:

  • PPARgamma is constitutively active in several tumor types, and its agonists exhibit anticancer properties.
  • Research on PPARgamma agonists in melanoma has yielded conflicting results, with some studies indicating potential benefits and others highlighting pro-proliferative effects.
  • The precise role and therapeutic potential of PPARgamma in melanoma remain incompletely understood, with significant side effects noted.

Conclusions:

  • PPARgamma represents a potential molecular target for melanoma therapy, but its application requires careful consideration.
  • Further research is needed to elucidate the complex role of PPARgamma in melanoma and to optimize the use of its agonists.
  • Balancing the potential benefits against the risks and side effects is crucial for developing effective PPARgamma-targeted melanoma treatments.

More Related Videos

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...